- Home
- LXRX vs KIO Comparison
LXRX vs KIO Comparison
Compare LXRX & KIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LXRX | KIO |
|---|---|---|
| Founded | 1995 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 547.4M | 470.1M |
| IPO Year | 2000 | 2011 |
Fundamental Metrics
Financial Performance| Metric | LXRX | KIO |
|---|---|---|
| Price | $1.66 | $10.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.15 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 314.3K |
| Earning Date | 03-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,803,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 60.24 | N/A |
| 52 Week Low | $0.33 | $10.67 |
| 52 Week High | $1.83 | $12.83 |
Technical Indicators
Market Signals| Indicator | LXRX | KIO |
|---|---|---|
| Relative Strength Index (RSI) | 55.24 | 40.24 |
| Support Level | $1.08 | N/A |
| Resistance Level | $1.81 | $12.51 |
| Average True Range (ATR) | 0.11 | 0.17 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 50.91 | 43.08 |
Price Performance
Historical ComparisonAbout LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.